The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
NCT ID: NCT06355427
Last Updated: 2025-04-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2/PHASE3
Total Enrollment
81 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-11-29
Study Completion Date
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background
Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually. Currently, surgical resection is the only curative option. However, patients are not eligible for surgery if the tumor cannot be resected or the cancer has spread. For this group of patients, palliative chemotherapy is the most suited treatment option. To find out if a patient is suited for surgery, CT and MRI are performed. These imaging techniques, however, struggle to correctly identify small cancer spreads that are smaller than 1 cm. Therefore, cancer that has already spread can be found during surgery. In these cases, the tumor cannot be removed and the surgery therefore has not been of any benefit for the patient. These surgeries could be avoided by implementing a diagnostic tool with significantly higher accuracy than those currently used. Single center studies have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique for determining metastases in tumors with prominent desmoplastic reactions, like cholangiocarcinoma. The investigators predict that implementation of preoperative FAPI PET-CT could prevent futile surgery for at least half of patients in whom intra-operative metastasized disease is found using the current work-up.
Patient population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria are previous abdominal surgery or chemotherapy, known pregnancy or lactation and indication for FDG PET-CT.
Participation in this study
Participation would mean to undergo FAPI PET-CT prior to the scheduled surgery. This will take up about half a day of the participant's time. Afterwards, participants receive questionnaires about quality of life and use of healthcare services over a period of six months in order for the researchers to be able to calculate the cost-effectiveness of additional FAPI PET-CT.
Risks and benefits of participation
Patients may benefit directly from \[18F\]F-FAPI PET-CT by allowing for more targeted treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical support instead, minimizing treatment delay. Avoiding futile surgery will also prevent patients from being exposed to the risks and discomfort associated with surgery: hospital stay, possibility of intraoperative or postoperative complications, postoperative pain and recovery, and mortality.
Potential risks and burdens associated with this study are an extra hospital visit and a time burden of approximately half a day. Risks associated with administering FAPI are (re)bleed and infection. Both risks have a minimal probability of onset and can usually easily be treated. As \[18F\]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, the risk of allergic reactions is expected to be minimal and no tissue damage is expected. The burden associated with undergoing a PET-CT may be laying still for a certain time, and possible experience of claustrophobia. Possible metastases of the cancer will have to be confirmed when suspicious findings are seen on FAPI PET-CT. This could mean that participants will have to undergo additional testing such as imaging (CT or MRI) or biopsy. Undergoing FAPI PET-CT prior to surgery will result in a surgical delay when compared with the current clinical practice. The investigators do not expect this delay to influence the patient's prognosis. Follow-up will result in a time burden for patients to answer questionnaires on a two-weekly or monthly basis.
Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually. Currently, surgical resection is the only curative option. However, patients are not eligible for surgery if the tumor cannot be resected or the cancer has spread. For this group of patients, palliative chemotherapy is the most suited treatment option. To find out if a patient is suited for surgery, CT and MRI are performed. These imaging techniques, however, struggle to correctly identify small cancer spreads that are smaller than 1 cm. Therefore, cancer that has already spread can be found during surgery. In these cases, the tumor cannot be removed and the surgery therefore has not been of any benefit for the patient. These surgeries could be avoided by implementing a diagnostic tool with significantly higher accuracy than those currently used. Single center studies have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique for determining metastases in tumors with prominent desmoplastic reactions, like cholangiocarcinoma. The investigators predict that implementation of preoperative FAPI PET-CT could prevent futile surgery for at least half of patients in whom intra-operative metastasized disease is found using the current work-up.
Patient population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria are previous abdominal surgery or chemotherapy, known pregnancy or lactation and indication for FDG PET-CT.
Participation in this study
Participation would mean to undergo FAPI PET-CT prior to the scheduled surgery. This will take up about half a day of the participant's time. Afterwards, participants receive questionnaires about quality of life and use of healthcare services over a period of six months in order for the researchers to be able to calculate the cost-effectiveness of additional FAPI PET-CT.
Risks and benefits of participation
Patients may benefit directly from \[18F\]F-FAPI PET-CT by allowing for more targeted treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical support instead, minimizing treatment delay. Avoiding futile surgery will also prevent patients from being exposed to the risks and discomfort associated with surgery: hospital stay, possibility of intraoperative or postoperative complications, postoperative pain and recovery, and mortality.
Potential risks and burdens associated with this study are an extra hospital visit and a time burden of approximately half a day. Risks associated with administering FAPI are (re)bleed and infection. Both risks have a minimal probability of onset and can usually easily be treated. As \[18F\]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, the risk of allergic reactions is expected to be minimal and no tissue damage is expected. The burden associated with undergoing a PET-CT may be laying still for a certain time, and possible experience of claustrophobia. Possible metastases of the cancer will have to be confirmed when suspicious findings are seen on FAPI PET-CT. This could mean that participants will have to undergo additional testing such as imaging (CT or MRI) or biopsy. Undergoing FAPI PET-CT prior to surgery will result in a surgical delay when compared with the current clinical practice. The investigators do not expect this delay to influence the patient's prognosis. Follow-up will result in a time burden for patients to answer questionnaires on a two-weekly or monthly basis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
NCT05957250
Pancreatic Cancer
Cholangiocarcinoma
RECRUITING
NA
Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT
NCT00823810
Colorectal Cancer
TERMINATED
NA
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
NCT05531045
Metastatic Colorectal Cancer
NOT_YET_RECRUITING
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
NCT07109440
Liver Metastases From Colorectal Cancer
RECRUITING
NA
Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study
NCT00604266
Cholangiocarcinoma
WITHDRAWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rationale
Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually. Currently, surgical resection is the only curative option. However, patients are not eligible for surgery if vascular invasion, distant tumor positive lymph nodes, peritoneal metastases or organ metastases are found on preoperative imaging. For this group of patients, palliative chemotherapy is the most suited treatment option. The preoperative imaging currently includes CT, MRI and FDG PET-CT. In around 29 % of potentially resectable tumors (based on preoperative imaging) metastases are found during subsequent surgery. These explorations could be avoided by implementing a diagnostic tool with significantly higher accuracy than those currently used. Single center studies have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique for determining metastases in tumors with prominent desmoplastic reactions, like cholangiocarcinoma. Our systematic review has shown it is superior to the commonly used FDG PET-CT for this indication. The investigators predict that implementation of preoperative FAPI PET-CT could alter treatment course for at least half (13%) of patients in whom intra-operative metastasized disease is found using the current work-up.
Objective
The primary aim of this study is to assess whether preoperative \[18F\]F-FAPI PET-CT in addition to standard preoperative imaging can successfully identify metastasized disease and change treatment plan in patients with potentially resectable proximal bile duct cancer (intrahepatic, perihilar and gall bladder cholangiocarcinoma). This study also aims to evaluate if adding \[18F\]F-FAPI PET-CT to preoperative imaging is cost-effective.
Main trial endpoints
The main endpoint is the diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of \[18F\]F-FAPI PET-CT.
Secondary trial endpoints
* Diagnostic accuracy of \[18F\]F-FAPI PET-CT per abdominal region and per lesion
* The number of additional significant findings on \[18F\]F-FAPI PET-CT
* Change of treatment: true change and virtual change
* The number of times readers' conclusions differed and why
* Cost-effectiveness analysis, budget impact analysis (BIA), sector costs, societal costs, health-related quality of life (HRQoL)
* The number of additional significant findings on \[18F\]F-FAPI PET-CT
* Number of days between date of first imaging (CT/MRI) and starting date of chemotherapy, palliative therapy or surgical resection
* The incidence and severity of AEs and SAEs according to CTCAEv5
* VOI, TTP, K1 and k2, SUV and TBR (in a subgroup of patients)
Trial design
Prospective multicenter observational cohort study, expected total duration 4 years. Participants will be participating for at least six months.
Trial population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria are previous abdominal surgery or chemotherapy, known pregnancy or lactation and indication for FDG PET-CT.
Interventions
If patients are deemed eligible for surgery (laparoscopy or laparotomy) by the weekly organ-specific multidisciplinary team (MDT) including an abdominal nuclear medicine specialist, radiologist, surgeon, gastroenterologist/hepatologist, oncologist and, optionally, pathologist, patients will be asked to participate in the study. After inclusion, patients will receive additional \[18F\]F-FAPI PET-CT. Patients who underwent \[18F\]F-FAPI PET-CT will undergo follow-up for at least six months, if clinically advisable. Follow-up includes information regarding additional imaging, surgery or complications. To determine cost-effectiveness, patients' medical consumption will be elicited using two questionnaires. Patients will be asked to fill out the 'institute for Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ)' at three and six months after their initial CT/MRI imaging (before \[18F\]F-FAPI PET-CT or surgery). Patients will also be asked to fill out the European Organisation for Research and Treatment of Cancer (EORTC) group's QLQ-C30 and QLQ-BIL21 questionnaires and the EuroQol (EQ) Group's EQ-5D-5L questionnaire once every two weeks during the first two months after \[18F\]F-FAPI PET-CT and then once every four weeks until six months follow-up.
Risks and benefits
Patients may benefit directly from \[18F\]F-FAPI PET-CT by allowing for more targeted treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical support instead, minimizing treatment delay. Avoiding futile surgery will also prevent patients from being exposed to the risks and discomfort associated with surgery: hospital stay, possibility of intraoperative or postoperative complications, postoperative pain and recovery, and mortality.
Potential risks and burdens associated with this study are an extra site visit and a time burden of approximately half a day. Risks associated with vena puncture are (re)bleed and infection. Both risks have a minimal probability of onset, and when anticipated upon, are not expected to have significant clinical consequences. Risks associated with the administration of the study agent are allergic reactions and radiation burden. \[18F\]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, which is why the risk of allergic reactions is expected to be minimal and no tissue damage is expected. The burden associated with undergoing a PET-CT may be laying still for a certain time, and possible experience of claustrophobia. Metastases will have to be confirmed when suspicious findings are seen on \[18F\]F-FAPI PET-CT. This could mean subjects will have to undergo additional testing such as imaging (CT or MRI) or biopsy. If these additional tests are negative for metastases, the subject's exploratory surgery will have been needlessly delayed. Having to undergo \[18F\]F-FAPI PET-CT prior to surgery will also result in a surgical delay when compared with the current clinical practice. The investigators do not expect this delay to influence the subject's prognosis. Follow-up will result in a time burden for patients to answer questionnaires on a two-weekly or monthly basis.
Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually. Currently, surgical resection is the only curative option. However, patients are not eligible for surgery if vascular invasion, distant tumor positive lymph nodes, peritoneal metastases or organ metastases are found on preoperative imaging. For this group of patients, palliative chemotherapy is the most suited treatment option. The preoperative imaging currently includes CT, MRI and FDG PET-CT. In around 29 % of potentially resectable tumors (based on preoperative imaging) metastases are found during subsequent surgery. These explorations could be avoided by implementing a diagnostic tool with significantly higher accuracy than those currently used. Single center studies have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique for determining metastases in tumors with prominent desmoplastic reactions, like cholangiocarcinoma. Our systematic review has shown it is superior to the commonly used FDG PET-CT for this indication. The investigators predict that implementation of preoperative FAPI PET-CT could alter treatment course for at least half (13%) of patients in whom intra-operative metastasized disease is found using the current work-up.
Objective
The primary aim of this study is to assess whether preoperative \[18F\]F-FAPI PET-CT in addition to standard preoperative imaging can successfully identify metastasized disease and change treatment plan in patients with potentially resectable proximal bile duct cancer (intrahepatic, perihilar and gall bladder cholangiocarcinoma). This study also aims to evaluate if adding \[18F\]F-FAPI PET-CT to preoperative imaging is cost-effective.
Main trial endpoints
The main endpoint is the diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of \[18F\]F-FAPI PET-CT.
Secondary trial endpoints
* Diagnostic accuracy of \[18F\]F-FAPI PET-CT per abdominal region and per lesion
* The number of additional significant findings on \[18F\]F-FAPI PET-CT
* Change of treatment: true change and virtual change
* The number of times readers' conclusions differed and why
* Cost-effectiveness analysis, budget impact analysis (BIA), sector costs, societal costs, health-related quality of life (HRQoL)
* The number of additional significant findings on \[18F\]F-FAPI PET-CT
* Number of days between date of first imaging (CT/MRI) and starting date of chemotherapy, palliative therapy or surgical resection
* The incidence and severity of AEs and SAEs according to CTCAEv5
* VOI, TTP, K1 and k2, SUV and TBR (in a subgroup of patients)
Trial design
Prospective multicenter observational cohort study, expected total duration 4 years. Participants will be participating for at least six months.
Trial population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria are previous abdominal surgery or chemotherapy, known pregnancy or lactation and indication for FDG PET-CT.
Interventions
If patients are deemed eligible for surgery (laparoscopy or laparotomy) by the weekly organ-specific multidisciplinary team (MDT) including an abdominal nuclear medicine specialist, radiologist, surgeon, gastroenterologist/hepatologist, oncologist and, optionally, pathologist, patients will be asked to participate in the study. After inclusion, patients will receive additional \[18F\]F-FAPI PET-CT. Patients who underwent \[18F\]F-FAPI PET-CT will undergo follow-up for at least six months, if clinically advisable. Follow-up includes information regarding additional imaging, surgery or complications. To determine cost-effectiveness, patients' medical consumption will be elicited using two questionnaires. Patients will be asked to fill out the 'institute for Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ)' at three and six months after their initial CT/MRI imaging (before \[18F\]F-FAPI PET-CT or surgery). Patients will also be asked to fill out the European Organisation for Research and Treatment of Cancer (EORTC) group's QLQ-C30 and QLQ-BIL21 questionnaires and the EuroQol (EQ) Group's EQ-5D-5L questionnaire once every two weeks during the first two months after \[18F\]F-FAPI PET-CT and then once every four weeks until six months follow-up.
Risks and benefits
Patients may benefit directly from \[18F\]F-FAPI PET-CT by allowing for more targeted treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical support instead, minimizing treatment delay. Avoiding futile surgery will also prevent patients from being exposed to the risks and discomfort associated with surgery: hospital stay, possibility of intraoperative or postoperative complications, postoperative pain and recovery, and mortality.
Potential risks and burdens associated with this study are an extra site visit and a time burden of approximately half a day. Risks associated with vena puncture are (re)bleed and infection. Both risks have a minimal probability of onset, and when anticipated upon, are not expected to have significant clinical consequences. Risks associated with the administration of the study agent are allergic reactions and radiation burden. \[18F\]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, which is why the risk of allergic reactions is expected to be minimal and no tissue damage is expected. The burden associated with undergoing a PET-CT may be laying still for a certain time, and possible experience of claustrophobia. Metastases will have to be confirmed when suspicious findings are seen on \[18F\]F-FAPI PET-CT. This could mean subjects will have to undergo additional testing such as imaging (CT or MRI) or biopsy. If these additional tests are negative for metastases, the subject's exploratory surgery will have been needlessly delayed. Having to undergo \[18F\]F-FAPI PET-CT prior to surgery will also result in a surgical delay when compared with the current clinical practice. The investigators do not expect this delay to influence the subject's prognosis. Follow-up will result in a time burden for patients to answer questionnaires on a two-weekly or monthly basis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cholangiocarcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FAPI PET-CT
Participants will undergo additional FAPI PET-CT prior to scheduled surgery.
Group Type
EXPERIMENTAL
[18F]F-FAPI PET-CT
Intervention Type
DRUG
\[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[18F]F-FAPI PET-CT
\[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is scheduled for explorative laparoscopy or laparotomy for suspicion of proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma)
* Tumor is regarded as resectable based on preoperative CT and MRI
* Patient is 18 years or older and is able to give informed consent
* Tumor is regarded as resectable based on preoperative CT and MRI
* Patient is 18 years or older and is able to give informed consent
Exclusion Criteria
* Previous abdominal surgery or chemotherapy
* Patient had FDG PET-CT in addition to preoperative CT and MRI
* Contra-indication for performing PET-CT
* Indication for FDG PET-CT
* Pregnancy or lactation, for the latter, temporary discontinuation may be considered.
* Known allergic reaction to therapeutic radiopharmaceuticals
* Inability to lie still on the back for the duration of PET-CT
* Impaired renal function, defined as eGFR (MDRD) \<25 ml/min/1,73 m2. An exception can be made in consultation with the treating physician.
* Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient\'s experience of study burden (such as non-suppressible claustrophobia)
* Patient had FDG PET-CT in addition to preoperative CT and MRI
* Contra-indication for performing PET-CT
* Indication for FDG PET-CT
* Pregnancy or lactation, for the latter, temporary discontinuation may be considered.
* Known allergic reaction to therapeutic radiopharmaceuticals
* Inability to lie still on the back for the duration of PET-CT
* Impaired renal function, defined as eGFR (MDRD) \<25 ml/min/1,73 m2. An exception can be made in consultation with the treating physician.
* Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient\'s experience of study burden (such as non-suppressible claustrophobia)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Sponsor Role
collaborator
UMC Utrecht
OTHER
Sponsor Role
collaborator
Mara Veenstra, MD
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mara Veenstra, MD
Coordinating Investigator
Responsibility Role
SPONSOR_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amsterdam UMC
Amsterdam, , Netherlands
Site Status
RECRUITING
Erasmus MC
Rotterdam, , Netherlands
Site Status
RECRUITING
UMC Utrecht
Utrecht, , Netherlands
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Netherlands
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-507938-24-00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
NCT06782412
RECRUITING
PHASE2/PHASE3
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
NCT05641896
COMPLETED
PHASE2
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
NCT05141643
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
NCT07018661
RECRUITING
PHASE2/PHASE3
The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases
NCT00145665
TERMINATED
PHASE1/PHASE2
Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
NCT03303469
TERMINATED
PHASE2
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
NCT02379377
RECRUITING
PHASE1
A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma
NCT06277206
COMPLETED
18F-FDOPA PET in Neuroendocrine Tumours
NCT02431715
NO_LONGER_AVAILABLE
Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer
NCT03077334
COMPLETED
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
NCT06644716
RECRUITING
NA
[18F]FPIA PET/CT Imaging in Patients With Solid Tumours
NCT04717674
UNKNOWN
PHASE2
Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic Adenocarcinoma
NCT05023291
TERMINATED
NA
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
NCT00323076
TERMINATED
PHASE1/PHASE2
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.
NCT00741481
COMPLETED
18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib
NCT02977754
COMPLETED
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
NCT01050283
TERMINATED
PHASE1
FAPI PET/CT for Lymph Node Staging in Colorectal Carcinoma
NCT05209750
UNKNOWN
NA
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
NCT01717391
COMPLETED
PHASE2
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer
NCT01542177
COMPLETED
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324
UNKNOWN
NA
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
NCT06706921
RECRUITING
PHASE4
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
NCT03318497
COMPLETED
PHASE2
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT03604315
RECRUITING
PHASE1
Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
NCT01659645
COMPLETED
EARLY_PHASE1